About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« NIH Implements New Policy on HeLa Genomic Data | Main | DuPont & Widener University School of Law IP CLE Seminar »

August 08, 2013


What is the final saying of federal circuit for chang patent (US7749532)

Dear rx007,

The Federal Circuit affirmed the district court decision in every respect except for the validity of those three claims. Therefore, because the lower court found the Chang patent infringed and not invalid, that is the status of that patent, at least with respect to the Mylan ANDA product. Thanks for the comment.


Maybe I am confused, but does the court mean that Galderma cannot prove infringement of a claim that required no significant inhibition of any of these microorganisms, because it is impractical, or even in principle? And if the latter, doesn't that mean that the Ashley patent doesn't satisfy the enablement requirement, since Galderma couldn't prove it either?
I apologize in advance if I have mangled this.

The comments to this entry are closed.

July 2024

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31